Finally, larger longer-term studies designed to detect differences in clinical outcomes relative to changes in FGF-23 and CKD-MBD markers of the observed magnitudes would be required to ascribe clinical significance to these findings. The gene discussed is FGF23; the disease is chronic kidney disease.